Guangzhou Xinji Pharmaceuticals Co., Ltd. ("Xinji Pharma") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Haitong International as its sole sponsor.

Founded in 2007 and headquartered in Guangzhou, China, Xinji Pharma is a clinical-stage biotech company focused on innovative drug development. The company has established two proprietary technology platforms: (i) a soluble microneedle patch platform and (ii) a nasal inhalation formulation platform.

Xinji Pharma's lead product is a dexmedetomidine hydrochloride microneedle patch developed for preoperative sedation in both pediatric and adult patients. As of December 18, 2025, the pediatric formulation has entered Phase IIa clinical trials in China, while the adult version has received NMPA approval for Phase II trials expected to begin in Q1 2026.

The company's second core product, XJN010, is a nasal inhalation formulation designed for on-demand treatment of "off" episodes in Parkinson's disease patients. XJN010 has progressed to Phase II clinical trials in China as of December 18, 2025.